Suppr超能文献

沙雷氏菌肽酶的局部制剂:研发与药效学评价。

Topical formulations of serratiopeptidase: development and pharmacodynamic evaluation.

作者信息

Nirale N M, Menon Mala D

机构信息

Department of Pharmaceutics, Bombay College of Pharmacy, Kalina, Santacruz (East), Mumbai-400 098, India.

出版信息

Indian J Pharm Sci. 2010 Jan;72(1):65-71. doi: 10.4103/0250-474X.62246.

Abstract

Serratiopeptidase, an enzyme derived from Serratia marcescences strain E-15 (ATCC 21074), present in the gut wall of the silk worm possesses anti-inflammatory properties, and can prove to be a suitable alternative to commonly used non steroidal antiinflammatory agents. Being sensitive to gastric degradation, serratiopeptidase is conventionally given orally in the form of enteric coated tablet formulations. Topical formulations of serratiopeptidase would be useful to treat local inflammations and may prove to be more effective compared to non steroidal antiinflammatory agents. The present study investigates the feasibility of developing topical preparations of serratiopeptidase in the form of ointments and gels. Excipient compatibility of serratiopeptidase with various excipients and polymers, formulation development, characterization and stability studies have been carried out. Stable formulation was evaluated for anti-inflammatory activity by oxazolone induced ear edema method in mice and allergenic potential by passive cutaneous anaphylaxis.

摘要

沙雷氏菌蛋白酶是一种从粘质沙雷氏菌菌株E-15(美国典型培养物保藏中心21074)中提取的酶,存在于蚕的肠壁中,具有抗炎特性,并且可以证明是常用非甾体抗炎药的合适替代品。由于对胃降解敏感,沙雷氏菌蛋白酶通常以肠溶包衣片剂制剂的形式口服给药。沙雷氏菌蛋白酶的局部制剂可用于治疗局部炎症,并且可能比非甾体抗炎药更有效。本研究调查了开发软膏和凝胶形式的沙雷氏菌蛋白酶局部制剂的可行性。已经进行了沙雷氏菌蛋白酶与各种赋形剂和聚合物的辅料相容性、制剂开发、表征和稳定性研究。通过恶唑酮诱导的小鼠耳部水肿法评估稳定制剂的抗炎活性,并通过被动皮肤过敏反应评估其致敏潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fea2/2883229/73ae7c962d24/IJPhS-72-65-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验